Fuji Photo Film Company, Limited

Chugai Seiyaku Kabushiki Kaisha

Fujifilm Celltec Co., Ltd.

Hajime Miyamoto

Tomoyuki Igawa

Akihiro Matsufuji

Nobufumi Mori

Hiroshi Fujimoto

Hiroyuki Tsunoda

Yoshio Idota

Atsuhiko Maeda

Taichi Kuramochi

Hideki Tomiyama

Tatsuhiko Tachibana

Hirotake Shiraiwa

Atsushi Matsuo

Akira Kase

Masahiko Murayama

Minoru Machida

Takehisa Kitazawa

Tsukasa Suzuki

Teruo Nakamura

Yasuo Sekimori

Yoshikatsu Kagawa

Hiromitsu Kawata

Shigehisa Nagahashi

An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the present invention have high antitumor activity, and are useful as agents for decreasing the AXL expression level, antitumor agents, and diagnostic agents for cancer.

Anti-AXL antibody

The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity.

Monoclonal antibody capable of binding to anexelekto, and use thereof

The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.

PEG-conjugated erythropoietin

A nonaqueous secondary battery is disclosed, comprising a positive electrode having a positive electrode active material, a negative electrode having a negative electrode material, and a nonaqueous electrolyte, wherein the positive electrode active material is a transition metal oxide capable of intercalating and deintercalating lithium, and the negative electrode material comprises at least one silicic material capable of intercalating and deintercalating lithium selected from silicon, a silicon alloy and a silicide, and a process for producing the nonaqueous secondary battery is disclosed.

Nonaqueous secondary battery containing silicic material

A nonaqueous secondary battery is disclosed, comprising a positive electrode sheet containing a lithium-containing transition metal oxide as a positive electrode active material, a negative electrode sheet having at least one layer containing a negative electrode material capable of intercalating and deintercalating lithium, and a nonaqueous electrolyte containing a lithium metal salt, wherein the battery into which an electrolytic solution has been injected is sealed, subjected to charging treatment having at least two stages, and subjected to storage treatment having at least two steps. A process for preparing such the nonaqueous secondary battery is also disclosed.

Nonaqueous secondary battery and process for preparation thereof

A silver halide photographic material comprises a silver halide emulsion layer and a surface backing layer provided on a support. The surface backing layer contains an aliphatic hydrocarbon compound represented by the formula (I) or (II)

Silver halide photographic material comprising emulsion layer and

A process for producing a silver halide photographic material comprising a polyester support having thereon at least one light-sensitive layer and at least one undercoat layer is described, wherein the undercoat layer is provided by coating a solution containing gelatin for an undercoating binder having a calcium ion (Ca.sup.++) content of from 10 to 2,500 ppm based on dry gelatin.

Process for producing silver halide photographic material

Growing community of inventors

Kanagawa, Japan

Hajime Miyamoto